Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rapid Micro Biosystems has entered into a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology division.
Subscribe to our email newsletter
As per the terms of the agreement, Rapid Micro Biosystems is expected to receive $2.2m in the first contract year and up to an additional $4.5m in two option years, for a total contract value of $6.7m.
Rapid Micro Biosystems said that faster microbiological quality control (QC) testing will reduce the release cycle of vaccines by as much as two to four weeks.
Rapid Micro Biosystems CEO Steve Delity said that they were pleased to be awarded this contract by BARDA.
Rapid Micro Biosystems, headquartered in Bedford, Massachusetts, is a provider of products for faster, automated detection of microbial contamination in the manufacture of pharmaceutical, biotechnology and personal care products.